Avg closing price
Price range

11 Seth Klarman Theravance Biopharma Trades

Seth Klarman acquired 13.6 Million Theravance Biopharma shares worth $123 Million. That's 1.59% of their equity portfolio (19th largest holding). The investor owns 18.3% of the outstanding Theravance Biopharma stock. The first Theravance Biopharma trade was made in Q2 2014. Since then Seth Klarman bought shares eight more times and sold shares on two occasions. The investor's estimated purchase price is $320 Million, resulting in a loss of 62%.

Avg closing price
Price range
Sold 0.1% shares (-16.8 Thousand shares) Q1 2022
Avg closing price $9.80
Price range $8.33 - $12.96
Increased shares by 37.8% (+3.75 Million shares) Q3 2021
Avg closing price $11.19
Price range $6.77 - $14.41
Increased shares by 13.5% (+1.18 Million shares) Q2 2021
Avg closing price $18.78
Price range $14.52 - $22.46
Sold 6.2% shares (-574 Thousand shares) Q3 2020
Avg closing price $18.73
Price range $14.78 - $22.49
Increased shares by 0.4% (+35.2 Thousand shares) Q3 2017
Avg closing price $32.70
Price range $23.88 - $42.56
Increased shares by 26.2% (+1.92 Million shares) Q4 2016
Avg closing price $31.02
Price range $24.57 - $38.58
Increased shares by 13.1% (+850 Thousand shares) Q2 2016
Avg closing price $21.59
Price range $17.45 - $24.20
Increased shares by 1.3% (+81 Thousand shares) Q1 2016
Avg closing price $16.36
Price range $13.35 - $18.80
Increased shares by 0.8% (+53.5 Thousand shares) Q2 2015
Avg closing price $15.51
Price range $12.57 - $18.63
Increased shares by 5.0% (+305 Thousand shares) Q1 2015
Avg closing price $18.33
Price range $14.70 - $21.73
New holding (+6.06 Million shares) Q2 2014
Avg closing price $30.10
Price range $23.51 - $34.87

Embed chart

Easily embed the chart on your blog or website – it will always update automatically!